Agonist News and Research

RSS

Targeted nanoparticles show promise in preventing pancreatic cancer spread to the liver

Pancreatic cancer remains one of the most challenging tumors to treat, partly because it is often discovered at advanced stages when the disease has already spread, or metastasized.

5 Mar 2025

Study shows benefits of GLP-1 drugs for kidney transplant recipients with type 2 diabetes

Kidney transplant recipients with type 2 diabetes treated with a new class of anti-obesity drugs were less likely to experience organ failure and survived longer, a new study shows.

5 Mar 2025

Surgery first strategy could lead to better weight loss outcomes

Mass General Brigham researchers found that total weight loss did not increase for patients who took semaglutide before having weight loss surgery, suggesting that a surgery first strategy could lead to better outcomes.

5 Mar 2025

New study confirms GLP-1 medications are safe for mental health in diabetes

Researchers assess whether GLP-1 receptor agonists increase the risk of suicide, self-harm, or suicidal ideation in type 2 diabetes patients.

2 Mar 2025

Genetic study demonstrates fat-selective weight loss with GLP-1 agonist use

Diabetes and obesity have become pressing health issues worldwide. Glucagon-like peptide-1 (GLP-1) receptor agonists, a class of medications widely used in the treatment of type 2 diabetes (T2D), have shown significant effectiveness in both lowering blood sugar levels and aiding weight loss due to their unique pharmacological mechanisms.

25 Feb 2025

Vitamin E significantly improves liver health in MASH patients, new study finds

A 96-week clinical trial found that 300 mg of Vitamin E significantly improved liver histology and reduced inflammation in patients with MASH, with no major safety concerns reported.

19 Feb 2025

Study uncovers molecular mechanisms behind insulin resistance in skeletal muscle

Insulin resistance precedes and predicts the onset of type 2 diabetes mellitus (DM2), a chronic disease that causes high morbidity and mortality worldwide.

19 Feb 2025

Opioid δ-receptor agonists show promise for treating IBS-like symptoms

Research reveals that δ-receptor agonists like KNT-127 alleviate IBS symptoms by modulating gut-brain interactions and reducing stress-induced hypermotility.

7 Feb 2025

Prescription trends for obesity medications surge, tied to growing interest in GLP-1 drugs

Obesity medication prescriptions reached 1.5 million, driven by GLP-1 agents semaglutide and tirzepatide, as public interest influences prescription trends.

3 Feb 2025

Revolutionizing diabetes care with innovative targets and therapeutic options

A thorough examination of modern drugs that target particular receptors and metabolic pathways for glucose and fat metabolism is presented. Recent research has revealed innovative targets and therapeutic options.

30 Jan 2025

Low-dose initiation of buprenorphine for people using fentanyl fails to deliver expected results

During the COVID-19 pandemic, when fentanyl overdoses surged, doctors were desperate to find ways of helping their patients.

24 Jan 2025

Why do people with obesity, but without diabetes, start taking semaglutide?

Research identifies key factors affecting semaglutide initiation among obese individuals without diabetes, revealing significant insurance coverage disparities.

22 Jan 2025

AstraZeneca's Pioneering Research in Heart Failure and ATTR-CM

Mina Makar highlights AstraZeneca's commitment to advancing heart failure research and innovative therapies, addressing critical needs in cardiovascular health.

16 Jan 2025

Semaglutide improves glycemic control with automated insulin delivery

Semaglutide combined with automated insulin delivery enhances glucose control in type 1 diabetes, lowering insulin requirements and aiding weight management.

15 Jan 2025

Uncovering the neurobiological mechanisms of delta opioid receptor agonists

The global burden of anxiety- and depression-related disorders is on the rise. While multiple drugs have been developed to treat these conditions, current medications have several limitations, including slow action and adverse effects with long-term use. This underscores the urgent need for novel, rapidly-acting therapeutic agents with minimal side effects.

15 Jan 2025

AI reveals key follicle sizes to boost IVF success

Researchers utilize explainable artificial intelligence to identify follicle sizes important for relevant downstream clinical outcomes during assisted conception.

14 Jan 2025

Statistical model analyzes the cost-effectiveness of semaglutide for non-diabetic obese individuals

For overweight or obese individuals without diabetes, but with pre-existing cardiovascular disease, semaglutide (Ozempic, Wegovy) is not cost-effective at current pricing, new research shows.

9 Jan 2025

GLP-1 drugs linked to fewer post-surgical complications in diabetic patients

People with diabetes who were taking GLP-1 receptor agonist drugs such as tirzepatide and semaglutide had significantly lower rates of hospital readmission, wound re-opening and hematoma after surgery, according to a large study led by investigators at Weill Cornell Medicine, Columbia University Vagelos College of Physicians and Surgeons and NewYork-Presbyterian.

6 Jan 2025

Study finds no clinical advantage of budesonide inhaler over fluticasone in COPD

A study compares budesonide-glycopyrrolate-formoterol and fluticasone-umeclidinium-vilanterol, revealing insights on COPD exacerbations and pneumonia risk.

6 Jan 2025

Kaempferol boosts immune tolerance and fights allergies

Kaempferol's role in Treg development is linked to Aldh1a2 activation in dendritic cells, highlighting its potential in suppressing inflammation and allergies.

19 Dec 2024